[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"colorectal-cancer-screening\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:colorectal-cancer-screening":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,28,0,25,[9,47,77,100,125,155,185,207,239,265,295,316,341,363,392,423,444,461,487,508,544,570,590,621,644],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100510698","impact-of-protect-your-colon-on-crc-screening-100510698",false,"NCT05929820","Impact of Protect Your Colon™ on CRC Screening","Pilot Randomized Controlled Trial Assessing the Impact of Protect Your Colon™ on Colorectal Cancer Screening Behaviors","Inclusion Criteria:\n\n* Individuals 45 to 75 years old\n* No prior CRC screening or not up-to-date with CRC screening\n* Not at high risk for CRC (e.g., inflammatory bowel disease, colon polyposis syndromes, family history of CRC)\n* No prior colon polyps\n* Additional inclusion criteria for participants recruited through Cint online survey panels: (i) appointment with a primary care provider up to 6 weeks from time of screening, and (ii) have Preferred Provider Organization (PPO) insurance.\n\nExclusion Criteria:\n\n* Does not speak English\n* Does not have internet access\n* Any records flagged \"break the glass\" or \"research opt out.\"","ALL","45 Years","75 Years",{"count":21,"type":22},184,"ESTIMATED","INTERVENTIONAL",[25],"NA","The purpose of the research is to assess the impact of Protect Your Colon™, a colorectal cancer (CRC) screening decision aid, on patients' CRC screening behaviors. The Investigators hypothesize that Protect Your Colon™, through optimizing shared decision making, will lead to selection of a test that accurately matches patients' values and increase CRC screening uptake. To test this hypothesis, the investigators will conduct a pilot randomized controlled trial (RCT) to assess if provision of Protect Your Colon™ improves communication on CRC screening, intent to complete screening, and ultimately uptake of screening vs. usual care.",[28],"Colorectal Cancer Screening",[30,31,32,33],"Decision aid","Stool test","Colonoscopy","CT scan","RECRUITING","2026-06-22",{"date":37,"type":38},"2026-06-25","ACTUAL",{"date":40,"type":38},"2023-09-28",{"date":42,"type":22},"2026-09-22",{"name":44,"class":45},"Cedars-Sinai Medical Center","OTHER",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":46},"100642653","optimizing-participation-in-colorectal-cancer-screening-by-direct-invitation-of-non-responders-by-general-practitionners-100642653","NCT07639554","Optimizing Participation In Colorectal Cancer Screening By Direct Invitation Of Non Responders By General Practitionners","Optimizing Participation In Colorectal Cancer Screening By Direct Invitation Of Non Responders By General Practitionners: A Randomized Controlled Cluster Trial","OPTIDEC COLO","Inclusion Criteria for general practionners :\n\n* Practise in one of the four departments of the Franche-Comté region; ractise in a solo practice, group practice, multidisciplinary primary care centre , or community health centre;\n* Are engaged in general medical practice.\n* Have agreed to participate in the study.\n\nInclusion Criteria for patients :\n\n* patients within the practice population of general practitioners selected to participate in the study;\n* aged between 50 and 75 years inclusive;\n* affiliated with the French general health insurance scheme or the agricultural social insurance scheme\n\nExclusion Criteria for general practionners:\n\n* practise exclusively in a specialty other than general practice (e.g. osteopathy, allergology, vascular medicine).\n\nNon inclusion Criteria for patients :\n\n\\- Objection expressed by the patient to the change in the purpose of data processing for research purposes",true,"50 Years","74 Years",{"count":59,"type":22},10000,[25],"The goal of this randomized trial is to assess the effectiveness of a targeted telephone reminder strategy, implemented by the patient's general practitioner, in enhancing participation in colorectal cancer screening among individuals who are not up to date . The participants are patients between 50 to 74 years old as they are the target for colorectal cancer screening. The main questions are:\n\n* What is the percentage of patients who completed the colorectal cancer screening test during the intervention year , within the patient population of general practitioners participating in the study and identified as non-up-to-date for their screening status ?\n* Identifying potential factors influencing the effectiveness of the intervention based on various characteristics of the patient, the geographical area, the general practitioner, and the caller\n\nResearchers will compare with other patients who are not up to date without the intervention of their general practionner with a telephone reminder.",[28],[64,65,66],"prevention","colorectal cancer screening","general practionner","NOT_YET_RECRUITING","2026-06-05",{"date":70,"type":38},"2026-06-10",{"date":72,"type":22},"2026-12-01",{"date":74,"type":22},"2028-03-01",{"name":76,"class":45},"MSPU des 3 Provinces",{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":55,"sex":17,"minAge":84,"maxAge":19,"enrollmentInfo":85,"targetDuration":4,"studyType":23,"phases":87,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":46},"100637810","electrolyte-beverage-combined-with-polyethylene-glycol-for-colonoscopy-bowel-preparation-100637810","NCT07608120","Electrolyte Beverage Combined With Polyethylene Glycol for Colonoscopy Bowel Preparation","Randomized Controlled Trial of Different Ratios of Electrolyte Beverage and Water Combined With Polyethylene Glycol on Bowel Preparation Quality and Ingestion Rhythm Before Colonoscopy","Inclusion Criteria:\n\n* Adults aged 18-75 years scheduled to undergo elective colonoscopy\n* Meet the standard clinical indications for colonoscopy;\n* Able to understand and comply with the bowel preparation procedure and complete oral polyethylene glycol (PEG) intake as required;\n* Able to comply with study-related data collection and follow-up;\n* Provide written informed consent voluntarily.\n\nExclusion Criteria:\n\n* Previously diagnosed colorectal cancer, intestinal obstruction, or suspected intestinal obstruction;\n* Active gastrointestinal bleeding or a definite history of gastrointestinal bleeding within the past 4 weeks (including melena, hematochezia, or hematemesis);\n* Severe renal insufficiency, decompensated heart failure, significant electrolyte imbalance, or other conditions unsuitable for PEG bowel preparation;\n* Known allergy to polyethylene glycol or components of the electrolyte beverage used in the study;\n* Pregnant or breastfeeding women;\n* Any other condition considered by the investigators to make the participant unsuitable for the study.","18 Years",{"count":86,"type":22},405,[25],"This randomized controlled trial aims to evaluate the effects of different ratios of electrolyte beverage and water combined with polyethylene glycol (PEG) on bowel preparation quality before colonoscopy. Participants undergoing elective colonoscopy will be randomly assigned to one of three bowel preparation regimens: PEG prepared with water only, PEG prepared with a low ratio of electrolyte beverage and water, or PEG prepared with a medium ratio of electrolyte beverage and water. The primary outcome is adequate bowel preparation assessed by the Boston Bowel Preparation Scale (BBPS). Secondary outcomes include bowel preparation completion rate, tolerability, adverse events, repeat colonoscopy rate, adenoma detection rate, and ingestion rhythm characteristics during bowel preparation. This study also aims to explore whether electrolyte beverage-assisted bowel preparation may improve bowel cleansing quality by influencing participants' ingestion rhythm and adherence during PEG intake.",[32,90,28],"Bowel Preparation Solutions","2026-05-24",{"date":93,"type":38},"2026-05-27",{"date":95,"type":38},"2026-05-18",{"date":97,"type":22},"2027-05-31",{"name":99,"class":45},"Nanfang Hospital, Southern Medical University",{"id":101,"slug":102,"hasResults":12,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":55,"sex":17,"minAge":108,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":23,"phases":111,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":46},"100639580","triton-15-robotic-system-for-diagnostic-colonoscopy-100639580","NCT07606963","Triton 1.5 Robotic System for Diagnostic Colonoscopy","Initial Clinical Experience With the Triton 1.5 Robotic System for Diagnostic Colonoscopy","CARE II","Inclusion Criteria:\n\n1. Age ≥ 22 years\n2. Adults indicated for elective screening, surveillance or diagnostic colonoscopy\n3. Subject is willing and able to provide written informed consent prior to receiving any non-standard of care protocol specific procedures\n4. Subject is willing and able to comply with all protocol required preparation and follow- up visits\n\nExclusion Criteria:\n\n1. Any medical or physical condition\u002Flimitation that would contraindicate a conventional colonoscopy. This assessment will be made by the investigator.\n2. Any active or magnetic implantable medical devices (e.g., pacemakers, defibrillators)\n3. Previous failed colonoscopy (except for inadequate bowel preparation)\n4. BMI \\> 45 kg\u002Fm2\n5. Pregnant participants, women of reproductive potential (pre-menopausal and\u002For no history of hysterectomy), confirmed by a positive pregnancy test (serum).\n6. Surgically altered colonic anatomy\n7. History of colorectal cancer, inflammatory bowel disease, polyposis syndrome, hereditary nonpolyposis colorectal cancer (Lynch) syndrome, sclerosing encapsulating peritonitis, active diverticulitis in last 6 months or toxic megacolon\n8. Lower gastrointestinal bleeding within 28 days prior to the colonoscopy day\n9. Known bleeding tendency such as hemophilia or coagulation factor deficiencies\n10. Subject receiving antiplatelet or anticoagulation therapy apart from low-dose aspirin\n11. Known colonic stricture\n12. Known risk factors for abdominal adhesions such as history of complex abdominal or pelvis surgical procedures, based on investigator assessment\n13. Known abdominal wall hernias\n14. History of radiotherapy to the abdomen or pelvis\n15. History of mesenteric ischemia\n16. Known coronary ischemia or cardiovascular stroke within 3 months prior to the colonoscopy procedure\n17. Contraindication to the proposed sedation \u002F anesthesia\n18. Received any investigational medicine or treatment within 28 days prior to the colonoscopy procedure\n19. Received or planning to receive any other endoscopic procedure within 4 weeks prior and 2 weeks after the colonoscopy procedure\n20. Participation in any concurrent clinical trial that may impact the results of this study\n\nIntra-Operative Criteria:\n\n1. Inadequate bowel preparation, defined as a Boston Bowel Preparation Scale (BBPS) (Appendix A) score \\\u003C 2 in any segment.\n2. Any intraoperative finding or condition that, in the Investigator's judgment, would make study participation unsafe or not in the subject's best interest (e.g., significant stricture, tight sigmoid colon precluding safe overtube passage).","22 Years",{"count":110,"type":22},40,[25],"This study is a prospective, single-arm, non-randomized, single-site study, focused on evaluating the safety and efficacy of the Triton 1.5 System in diagnostic and basic therapeutic colonoscopy.",[32,28,114,115],"Colorectal Neoplasms","Gastrointestinal Endoscopy",{"date":117,"type":38},"2026-05-26",{"date":119,"type":22},"2026-08-01",{"date":121,"type":22},"2026-10-15",{"name":123,"class":124},"Neptune Medical","INDUSTRY",{"id":126,"slug":127,"hasResults":12,"nctId":128,"briefTitle":129,"officialTitle":130,"acronym":131,"eligibilityCriteria":132,"healthyVolunteers":55,"sex":17,"minAge":133,"maxAge":57,"enrollmentInfo":134,"targetDuration":4,"studyType":136,"phases":4,"briefSummary":137,"conditions":138,"keywords":141,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":46},"100573055","improving-colorectal-cancer-early-screening-in-portugal-identification-of-gut-microbiome-biomarkers-in-stool-gutbiome-pt-100573055","NCT06741293","Improving Colorectal Cancer Early Screening in Portugal: Identification of Gut Microbiome Biomarkers in Stool (GUTBIOME-PT)","Improving Colorectal Cancer Early Screening in Portugal: Identification and Validation of Biomarkers of Gut Microbiome in Stool","GUTBIOME-PT","Inclusion Criteria:\n\n* Ability to provide written informed consent and comply with study procedures\n* Reside in the Lisbon Metropolitan Area,, Portugal\n* Age from 40 to 74 years\n\nExclusion Criteria:\n\n* Age \\\u003C 40 years or ≥ 75 years\n* Unable to provide informed consent\n* Refusal to provide stool samples\n* Active oncological disease\n* Personal history of CRC\n* Personal history of colon adenomas removed in the last 24 months\n* First-degree family history of CRC\n* Previous diagnosis of inflammatory bowel disease (ulcerative colitis, Crohn's disease or indeterminate colitis), inflammatory bowel syndrome, persistent and infectious gastroenteritis, colitis or gastritis, persistent or chronic diarrhoea of unknown aetiology or recurrent infection by Clostridioides difficile\n* Severe cardiovascular or heart diseases with medical diagnosis\n* Severe renal failure requiring hemodialysis\n* Severe lung disease\n* Pregnancy","40 Years",{"count":135,"type":22},30000,"OBSERVATIONAL","Colorectal cancer (CRC) is a major public health problem, responsible for 2 million new cases and almost 1 million deaths annually worldwide. In Portugal, as of 2022, CRC is the most common cancer, with 10,575 new cases reported, and the second leading cause of cancer-related mortality, accounting for 4,809 deaths (approximately 14% of all cancer-related deaths). In recent years, there has been an alarming increase in the incidence and mortality of CRC in people \\\u003C50 years of age.\n\nEarly detection is crucial, as survival rates decline sharply from 90% when detected early to just 10% in advanced stages. Non-invasive diagnostic tests, such as the Faecal Immunochemical Test (FIT), have a low sensitivity for early-stage lesions and a high rate of false positives. Therefore, there is an urgent need to improve non-invasive diagnostic methods for the early detection of CRC, as effective screening can prevent it by detecting and removing premalignant lesions.\n\nRecent studies suggest that an altered gut microbiota may confer susceptibility to certain types of cancer. Interestingly, the gut microbiota of patients with adenomas or CRC differs from that of healthy individuals. This study aims to identify gut microbiome biomarkers in faecal samples associated with CRC and\u002For high-risk adenomas to improve early detection.",[28,139,140],"Colorectal Cancer (CRC)","Microbiome",[142,143,65,144,145],"colorectal cancer","microbiome","biomarkers","metagenomics","2026-05-11",{"date":148,"type":38},"2026-05-14",{"date":150,"type":38},"2023-11-28",{"date":152,"type":22},"2029-11-28",{"name":154,"class":45},"Gulbenkian Institute for Molecular Medicine",{"id":156,"slug":157,"hasResults":12,"nctId":158,"briefTitle":159,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":12,"sex":17,"minAge":162,"maxAge":57,"enrollmentInfo":163,"targetDuration":4,"studyType":23,"phases":165,"briefSummary":166,"conditions":167,"keywords":170,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":46},"100579674","lifestyle-intervention-among-participants-of-the-french-colorectal-cancer-screening-program-life-screen-100579674","NCT06827366","Lifestyle Intervention Among Participants of the French Colorectal Cancer Screening Program (LIFE-SCREEN)","LIFE-SCREEN","Inclusion Criteria:\n\n* Having read the information note and agreeing to participate\n* Will and availability to be committed for a full year\n* At high risk for CRC but CRC negative\n* Affiliated to a health security system\n* Having a score on the adherence to the recommendation lower than or equal to 7 out of 9 at baseline.\n* Able to read, write and understand French\n\nExclusion Criteria:\n\n* Under a strict diet such as meal replacements, diets for co-morbidities such as diabetes\n* Immobile due to physical constraints (e.g. handicap that is not compatible with physical activities)\n* Extensive intestinal surgery such as colectomy or surgical resection of the colon\n* Chronic gastrointestinal illness (IBD, IBS, celiac disease)\n* Colorectal cancer confirmed or history of a primary cancer\n* Severe malnutrition\n* Pregnant\n* Participation in another lifestyle study\n\nNB : For this study, there is no exclusion period from other research, and participants can simultaneously take part in another study unless it concerns lifestyle.","35 Years",{"count":164,"type":22},800,[25],"The investigators propose a randomized controlled trial to develop and evaluate the impact of promoting advice on diet and lifestyle recommendations for cancer prevention at colorectal cancer screening among individuals who may be at higher risk for colorectal cancer (CRC). The specific objectives of this study are to 1) develop a lifestyle intervention based on evidenced-based diet and lifestyle recommendations (i.e. those proposed by the World Cancer Research Fund (WCRF) and the French National Cancer Institute); 2) evaluate the effect of the intervention on the adherence to the target diet and lifestyle recommendations as well as other subjective health measures, including quality of life; 3) evaluate the effect of the intervention on anthropometrics.",[28,168,169],"Colorectal Cancer Prevention","Colorectal Cancer",[142,171,172,173,174,175],"primary prevention","screening","physical activity","nutrition","recommendations","2026-04-29",{"date":178,"type":38},"2026-05-05",{"date":180,"type":38},"2026-01-26",{"date":182,"type":22},"2028-02-15",{"name":184,"class":45},"Centre Leon Berard",{"id":186,"slug":187,"hasResults":12,"nctId":188,"briefTitle":189,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":191,"targetDuration":4,"studyType":23,"phases":193,"briefSummary":194,"conditions":195,"keywords":196,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":46},"100620745","pilot-testing-of-a-colorectal-cancer-education-program-100620745","NCT07361614","Pilot Testing of a Colorectal Cancer Education Program","Inclusion Criteria:\n\n1. Age 45-75 years\n2. Not guideline concordant (no stool testing for CRC within past 1 year)\n3. No colonoscopy in past 10 years; no sigmoidoscopy or CT colonography in past 5 years)\n4. Understands English or Chinese languages.\n5. Willing and able to consent to participate\n\nExclusion Criteria:\n\n1\\) history of CRC or colectomy",{"count":192,"type":22},50,[25],"The primary objective of this study is to assess the feasibility, acceptability, and preliminary efficacy of a culturally and linguistically targeted, colorectal cancer (CRC) education program to improve CRC screening completion.",[28],[197,198],"CRC","Colorectal","2026-04-23",{"date":176,"type":38},{"date":202,"type":38},"2026-02-05",{"date":204,"type":22},"2027-08-31",{"name":206,"class":45},"NYU Langone Health",{"id":208,"slug":209,"hasResults":12,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":55,"sex":214,"minAge":215,"maxAge":216,"enrollmentInfo":217,"targetDuration":4,"studyType":23,"phases":219,"briefSummary":220,"conditions":221,"keywords":225,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":46},"100588307","social-media-based-education-on-cancer-screening-awareness-in-women-a-randomized-controlled-trial-100588307","NCT06939699","Social Media-Based Education on Cancer Screening Awareness in Women: A Randomized Controlled Trial","The Effect of Social Media-Based Education on Women's Knowledge, Attitudes, and Health Literacy Regarding Cancer Screenings: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Female participants aged 30 to 70 years\n* Use Instagram and\u002For WhatsApp actively\n* Literate and able to complete online forms\n* Voluntarily consent to participate\n\nExclusion Criteria:\n\n* Diagnosed with any type of cancer\n* Have undergone previous cancer screening","FEMALE","30 Years","70 Years",{"count":218,"type":22},132,[25],"This randomized controlled trial investigates the impact of a social media-based educational program on women's knowledge, attitudes, and digital health literacy regarding breast, cervical, and colorectal cancer screenings. The intervention is based on the Socio-Ecological Model and aims to improve awareness and screening participation. Participants in the intervention group receive daily educational content for 8 weeks via social media platforms (WhatsApp\u002FInstagram), while the control group receives two standard online education sessions via Microsoft Teams app. The study includes 132 women aged 30 to 70 in Türkiye who have not previously participated in cancer screenings. The primary outcomes include changes in cancer knowledge, attitudes, and digital health literacy levels measured by validated scales.",[222,223,28,224],"Cervical Cancer Screening","Breast Cancer Screening","Digital Health Literacy",[226,227,228,229,230],"internet based intervention","cancer screening","social media","health literacy","education","2026-04-22",{"date":199,"type":38},{"date":234,"type":22},"2026-07-15",{"date":236,"type":22},"2026-08-20",{"name":238,"class":45},"Emine Ergin",{"id":240,"slug":241,"hasResults":12,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":12,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":23,"phases":248,"briefSummary":249,"conditions":250,"keywords":252,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":262,"leadSponsor":263,"locationsCount":4},"100634547","cancer-awareness-among-syrian-migrants-100634547","NCT07541105","Cancer Awareness Among Syrian Migrants","A Theory-Driven Educational Intervention to Enhance Cancer Screening Uptake Among Syrian Migrants in Turkey: A Study Protocol","Inclusion Criteria:\n\n* over 18 years of age\n* hold Syrian citizenship\n* be registered with the Migrant Health Center in Mersin province\n* have proficiency in Turkish or Arabic\n* voluntarily agree to participate\n\nExclusion Criteria:\n\n* if they hold Turkish citizenship\n* have a diagnosed psychiatric disorder\n* have been diagnosed with cancer\n* wish to withdraw from the study",{"count":247,"type":22},30,[25],"This study aims to develop and evaluate a theory-based educational intervention to improve cancer screening participation among Syrian migrants in Turkey. The study will also develop a Cancer Protection Motivation Scale (CPMS) to measure individuals' motivation toward cancer screening. Using a mixed-methods design, the study will explore barriers, beliefs, and behaviors related to breast, cervical, and colorectal cancer screening. The effectiveness of the intervention will be assessed using a pretest-posttest design. The findings are expected to support culturally appropriate strategies to improve cancer screening uptake among migrant populations.",[223,222,28,251],"Cancer Prevention Behavior",[253,254,255,256,257],"Breast cancer","Colon cancer","Cervical cancer","Protection motivation","Reduced inequalities","2026-04-20",{"date":260,"type":38},"2026-04-24",{"date":258,"type":22},{"date":234,"type":22},{"name":264,"class":45},"Toros University",{"id":266,"slug":267,"hasResults":12,"nctId":268,"briefTitle":269,"officialTitle":269,"acronym":270,"eligibilityCriteria":271,"healthyVolunteers":55,"sex":17,"minAge":84,"maxAge":272,"enrollmentInfo":273,"targetDuration":4,"studyType":23,"phases":275,"briefSummary":276,"conditions":277,"keywords":281,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":46},"100634610","the-impact-of-image-assisted-colonoscope-on-patient-experience-physician-workload-and-examination-quality-100634610","NCT07541924","The Impact of Image-Assisted Colonoscope on Patient Experience, Physician Workload, and Examination Quality","LOOP-p1","Inclusion Criteria:\n\n* Age 18-80 years, or expected natural survival \\>3 years\n* Undergoing colonoscopy at Peking Union Medical College Hospital\n* Presence of an abdominal\u002Fpelvic CT scan performed within ≤5 years and no - - - major abdominal surgery afterward\n* Patient or legal guardian able to understand the study and provide written consent\n\nExclusion Criteria:\n\n* No available CT or CT quality insufficient for anatomical evaluation\n* Prior colonic surgery affecting anatomy (e.g., right hemicolectomy, transverse colectomy)\n* Severe cardiopulmonary dysfunction or coagulopathy\n* Pregnancy\n* Refusal to participate or inability to complete questionnaires\n* Patient or guardian unable to understand study requirements","80 Years",{"count":274,"type":22},200,[25],"Colonoscopy is the cornerstone for colorectal cancer screening, diagnosis, and post-treatment surveillance. Procedural quality is influenced by patient anatomy, particularly variations in colonic configuration such as sigmoid redundancy, looping, and low-lying transverse colon. These features prolong insertion time, increase patient discomfort, and elevate physician workload.\n\nEvidence suggests that prior CT imaging can provide objective and individualized information on colonic anatomy-such as redundancy, angulation, and tortuosity-potentially predicting procedural difficulty. However, existing studies are mainly retrospective or descriptive, lacking prospective randomized evidence on clinical utility.\n\nThis single-blind, randomized controlled trial evaluates whether image-assisted colonoscope insertion, based on pre-existing abdominal\u002Fpelvic CT scans, can improve cecal intubation time, enhance patient experience, reduce operator workload, and improve overall examination quality compared with standard colonoscopy.",[28,278,279,280],"Colonic Polyps\u002FColonoscopy\u002FColorectal Neoplasms","Difficult Colonoscopy","Colonoscopy-Related Discomfort",[32,282,283,284,285],"Cecal Intubation Time","Looping","Image-Assisted Colonoscopy","Personalized Colonoscopy","2026-04-14",{"date":288,"type":38},"2026-04-21",{"date":290,"type":38},"2025-12-09",{"date":292,"type":22},"2026-05-28",{"name":294,"class":45},"DONG WU",{"id":296,"slug":297,"hasResults":12,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":302,"targetDuration":4,"studyType":23,"phases":304,"briefSummary":305,"conditions":306,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":46},"100633091","animated-storytelling-to-promote-colorectal-cancer-screening-100633091","NCT07522177","Animated Storytelling to Promote Colorectal Cancer Screening","Using Short Animated Storytelling to Increase Intent for Colorectal Cancer Screening: A U.S. Online Randomized Controlled Trial","Inclusion Criteria:\n\n* Resides in the United States\n* Able to read and understand English\n* Self-reports not having completed colorectal cancer screening\n* Provides electronic informed consent\n\nExclusion Criteria:\n\n* Prior diagnosis of colorectal cancer\n* Self-reported completion of colorectal cancer screening",{"count":303,"type":22},3000,[25],"This online randomized controlled trial will evaluate whether a short animated storytelling video increases behavioral expectation to obtain colorectal cancer screening among screening-eligible U.S. adults who report not yet having completed screening. Participants will be recruited via Prolific and randomized in Stanford Qualtrics to view either a brief animated video or a time-neutral informational text. Outcomes will be assessed immediately after exposure.",[28],"2026-04-03",{"date":309,"type":38},"2026-04-13",{"date":311,"type":22},"2026-06",{"date":313,"type":22},"2026-08",{"name":315,"class":45},"Stanford University",{"id":317,"slug":318,"hasResults":12,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":322,"eligibilityCriteria":323,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":19,"enrollmentInfo":324,"targetDuration":4,"studyType":23,"phases":326,"briefSummary":328,"conditions":329,"keywords":330,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":46},"100632968","phase-3-effectiveness-of-early-information-and-endorsment-by-gp-to-increase-colonoscopy-follow-up-and-reduce-delays-in-people-with-a-positive-colorectal-cancer-screening-test-suivicolo-100632968","NCT07520578","EFFECTIVENESS OF EARLY INFORMATION AND ENDORSMENT BY GP TO INCREASE COLONOSCOPY FOLLOW-UP AND REDUCE DELAYS IN PEOPLE WITH A POSITIVE COLORECTAL CANCER SCREENING TEST. (SUIVICOLO)","EFFECTIVENESS OF EARLY INFORMATION AND ENDORSMENT BY GP TO INCREASE COLONOSCOPY FOLLOW-UP AND REDUCE DELAYS IN PEOPLE WITH A POSITIVE COLORECTAL CANCER SCREENING TEST, A RANDOMISED CONTROLLED TRIAL. (SUIVICOLO)","SUIVICOLO","Inclusion Criteria:\n\n* Aged between 50 and 75 at the time of the positive colorectal cancer screening test\n\n  * Residing in one of the departments of the Centre Val de Loire region\n  * Date on which the positive CRC screening test result was sent to the beneficiary recorded\n  * Colorectal cancer screening test results sent to the beneficiary within 30 days of the test being read\n  * Affiliated with a health insurance fund\n\nExclusion Criteria:\n\n* Subjects who have notified their refusal to allow their data to be used for research purposes will be excluded from the analyses.",{"count":325,"type":22},2000,[327],"PHASE3","To be effective, organized colorectal cancer screening requires good adherence to diagnostic colonoscopy in the event of a positive test. In France, the rate of diagnostic colonoscopy following a positive colorectal cancer screening test is less than 85%, and the median delay is close to 90 days. After receiving their positive result from the laboratory, individuals with no known follow-up are contacted only six months later by the Regional Cancer Screening Coordination Centers (CRCDC) responsible for following up with individuals who have tested positive. To optimize follow-up with colonoscopy, earlier contact and information about colonoscopy appear to be necessary. The contribution of the general practitioner identified on the test could be an additional lever.\n\nThe SUIVICOLO study aims to evaluate the effectiveness on the rate of colonoscopies performed at 6 months of two strategies for optimizing the follow-up of positive results in comparison with control group C (current procedures of the CRCDC Centre Val de Loire without early letter).\n\nThe two strategies evaluated will be:\n\n* Group B1: Sending an early letter signed by the CRCDC accompanied by information leaflet about colonoscopy\n* Group B2: Sending an early letter co-signed by the CRCDC and the general practitioner (identified or provided by the patient on the test identification form) accompanied by information leaflet about colonoscopy.\n\nThese strategies will be compared to the current follow-up strategy in a three arm randomized controlled arm.",[28],[32,331],"Fecal immunochemical test","2026-04-02",{"date":334,"type":38},"2026-04-09",{"date":336,"type":22},"2026-03-24",{"date":338,"type":22},"2028-10-24",{"name":340,"class":45},"University Hospital, Caen",{"id":342,"slug":343,"hasResults":12,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":347,"eligibilityCriteria":348,"healthyVolunteers":12,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":349,"targetDuration":4,"studyType":23,"phases":351,"briefSummary":352,"conditions":353,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":46},"100521818","impact-of-training-patient-centered-approach-on-shared-decision-in-colorectal-cancer-screening-100521818","NCT06074536","Impact of Training Patient-centered Approach on Shared Decision in Colorectal Cancer Screening","Impact of Training in the Patient-centered Approach on Shared Decision-making in the Colorectal Cancer Screening: a Cluster Randomized Trial","FACELE","Inclusion Criteria:\n\n* Patient aged 50 to 74:\n* Eligible for organized CRC screening,\n* Having declared as attending clinician a general practitioner investigator of the study\n\n  ✓ Consulting their attending clinician for the duration of the study,\n* AND able and willing to comply with all trial requirements\n\nNon inclusion Criteria:\n\n\\- ✓ Screened for CRC less than 2 years ago\n\n* Not eligible for organized CRC screening:\n\n  * History of adenomas or CRC:\n\n    \\- Family (1st degree)\n  * Personal history of IBD:\n\n    * Crohn's disease\n    * Ulcerative colitis)\n  * Hereditary predispositions:\n\n    * Familial adenomatous polyposis\n    * Hereditary non-polyposis colorectal cancer (Lynch syndrome)\n* Patient with symptoms requiring colonoscopy\n* Having a level of literacy that does not allow the completion of the self-questionnaire.\n* Having an inability to give express consent.\n* Being under guardianship, curatorship or having cognitive disorders",{"count":350,"type":22},400,[25],"The purpose of this study is to compare the effect of face-to-face training of general practitioners on the implementation of a shared decision (in the context of colorectal cancer screening), versus current practice (i.e. without training in the patient-centered approach).",[28],"2026-02-09",{"date":356,"type":38},"2026-02-11",{"date":358,"type":38},"2024-03-06",{"date":360,"type":22},"2027-11-30",{"name":362,"class":45},"CNGE Conseil",{"id":364,"slug":365,"hasResults":12,"nctId":366,"briefTitle":367,"officialTitle":367,"acronym":4,"eligibilityCriteria":368,"healthyVolunteers":12,"sex":17,"minAge":369,"maxAge":370,"enrollmentInfo":371,"targetDuration":4,"studyType":23,"phases":373,"briefSummary":374,"conditions":375,"keywords":379,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":391},"100541709","total-underwater-colonoscopy-tuc-for-improved-colorectal-cancer-screening-a-randomized-controlled-trial-100541709","NCT06333392","Total Underwater Colonoscopy (TUC) for Improved Colorectal Cancer Screening: A Randomized Controlled Trial","Inclusion Criteria:\n\n* All individuals referred to colonoscopy after a positive FIT screening at the participating screening centres\n\nExclusion Criteria:\n\n* Individuals with a CRC diagnosis within the last 10 years.","55 Years","60 Years",{"count":372,"type":22},1070,[25],"Colorectal cancer (CRC), the third most diagnosed cancer and second most common cause of cancer death. CRCs develop from precursors like adenomas (about 70% of CRCs) or serrated lesions (SSLs) (about 25-30% of CRCs). Colonoscopy is the cornerstone in CRC screening, in screening programmes often as a work-up examination after a positive primary screening test such as faecal immunochemical test (FIT). Norway and Sweden have recently launched a nationwide faecal haemoglobin CRC screening programmes. Recently, both a Dutch and an Austrian study showed that SSL detection rate (SSLDR) is inversely correlated to CRC at follow-up. Consequently, improved SSLDR can reduce the risk of post-colonoscopy CRC. SSLs are typically located in the right colon. They are flat, with indistinctive boarders, and consequently easily missed or incompletely resected. A Norwegian study showed incomplete resection of 40% of proximal SSLs. The prevalence of SSLs is higher in women than in men, with women being on a threefold risk of developing CRC from SSLs. It seems like post-colonoscopy CRC more often is caused by SSLs than by adenomas. Total underwater colonoscopy (TUC) is a technique replacing conventional CO2 insufflation by water infusion to distend the lumen and visualise the mucosa during withdrawal of the colonoscope and simultaneously removal of water. There are several reasons to advocate TUC:\n\n1. SSLs will be more visible as they \"float\" on the submucosa and contract into the lumen, while full distension by gas stretches the mucosa, making detection of flat lesions more difficult.\n2. Water works like a magnifying lens, making detection and detailed characterisation of lesions easier.\n3. uEMR is eased.\n4. Improved bowel cleansing\n\nThe goal of this clinical trial is to compare colonoscopy outcomes for standard gas (CO2) insufflation and TUC during withdrawal in patients participating in colonoscopy in the Norwegian and Swedish colorectal cancer screening programme after a positive fecal immunochemical test.\n\nThe overarching research questions of the present trial is whether colonoscopy outcomes are improved when CO2 insufflation is replaced by TUC during withdrawal and whether the new technique reduces the ecological footprint of the colonoscopy examination.\n\nThe project has five main hypotheses:\n\n1. TUC is superior to the standard approach (CO2 withdrawal) regarding detection of proximal SSLs.\n2. TUC increases the rate of complete resection of lesions \\>= 10mm.\n3. TUC reduces the rate of painful colonoscopies and vasovagal reactions.\n4. TUC reduces the health care costs by reduced use of single use accessories and reduced number of redundant colonoscopies to obtain polypfree colon.\n5. TUC reduces the carbon footprint by reduced use of single use accessories.\n\nIf TUC is superior to gas insufflation, the technique may be implemented rapidly since the technique is easy to learn. This study will increase endoscopy competence at participating centres. The centres are involved in national colonoscopy training programs, so the technique will quickly be passed on to other hospitals and screening centres.\n\nThe trial can be linked to three of the Global Goals:\n\n* Good health and well-being: The increased detection and improved complete removal of sessile serrated lesions can subsequently decrease the risk of CRC and CRC mortality during follow-up. TUC will probably reduce the rate of painful procedures and vasovagal reactions and thus increase the acceptance of a screening programme. Consequently, the project can contribute significantly to improve screening effectiveness in Norway and Sweden, particularly in women (women have a higher risk for SSLs and a higher risk of colorectal cancer developing from this type of precursor).\n* Gender equality: Women have a similar lifetime risk for CRC as men but less benefit of screening regardless of whether they are screened by sigmoidoscopy, FIT or colonoscopy. The reason is probably missed sessile serrated lesions in the proximal colon. If TUC improves SSLDR and complete lesion resection, this may lead to an equal benefit from CRC screening for women and men. Women have also a higher risk of discomfort and pain during colonoscopy than men. It has been shown that women prefer non-invasive screening modalities, potentially to avoid pain during colonoscopy, even if colonoscopy may be the most beneficial screening method for women. If TUC reduces the rate of painful colonoscopies, it can reduce women's barriers to attend screening.\n* Responsible consumption and production: The TUC technique will also reduce the ecological footprint of colonoscopy activity due to reduced consumption of single use accessories and reduced number of colonoscopies to achieve polyp free colon. Furthermore, the cost for the health care system will be substantially reduced.",[376,377,169,28,378],"Colorectal Neoplasia","Screening Colonoscopy","Vasovagal Reaction",[65,380,381],"screening colonoscopy","underwater colonoscopy","2025-12-12",{"date":384,"type":38},"2025-12-19",{"date":386,"type":38},"2024-10-23",{"date":388,"type":22},"2027-06",{"name":390,"class":45},"Vestre Viken Hospital Trust",5,{"id":393,"slug":394,"hasResults":12,"nctId":395,"briefTitle":396,"officialTitle":396,"acronym":397,"eligibilityCriteria":398,"healthyVolunteers":55,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":399,"targetDuration":4,"studyType":136,"phases":4,"briefSummary":401,"conditions":402,"keywords":408,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":414,"lastUpdatePostDateStruct":415,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":421,"locationsCount":46},"100610220","a-noninvasive-and-screening-mirna-signature-for-gastrointestinal-cancer-100610220","NCT07224750","A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer","MiGIC","Inclusion Criteria:\n\n1. Adults aged 18 years or older at the time of blood sample collection.\n2. Patients with a confirmed diagnosis of one of the following gastrointestinal cancers: Hepatocellular carcinoma (HCC), Cholangiocarcinoma (CCA), Pancreatic ductal adenocarcinoma (PDAC), Esophageal squamous cell carcinoma (ESCC), Gastric cancer (GC), Colorectal cancer (CRC), Non-cancer control participants, including healthy volunteers or patients with benign gastrointestinal conditions.\n3. Availability of retrospective blood samples collected according to institutional protocols.\n4. Willingness to allow use of de-identified clinical and demographic data for research purposes.\n\nExclusion Criteria:\n\n* other active malignancies; insufficient sample quality\u002Fvolume; recent chemotherapy\u002Fradiotherapy\u002Fsurgery; any condition preventing reliable participation.",{"count":400,"type":22},1000,"Gastrointestinal (GI) cancers remain a major global health burden, largely due to the lack of effective and accessible early screening strategies. Current diagnostic approaches-including endoscopy, computed tomography (CT), and magnetic resonance imaging (MRI)-are either invasive, resource-intensive, or insufficiently sensitive for detecting early-stage disease, and are therefore not suitable for population-wide screening or for simultaneously identifying multiple GI tumor types. As a result, many patients are diagnosed at advanced stages, when therapeutic options are limited and prognosis is poor.\n\nCirculating microRNAs (miRNAs) offer a promising alternative, as they are stable in peripheral blood and reflect tumor-related molecular alterations. In this study, the investigators aim to develop and validate a robust, noninvasive miRNA-based signature capable of distinguishing GI cancers from non-malignant controls. By integrating multi-cohort datasets and applying machine learning-based feature selection and predictive modeling, the investigators will construct a screening panel optimized for reproducibility, scalability, and early-stage detection. This noninvasive miRNA signature has the potential to support accessible, cost-effective, and clinically practical population-level screening for GI cancers, ultimately facilitating earlier diagnosis and improving outcomes for participants.",[403,404,405,406,407,28],"Hepatocellular Carcinoma (HCC)","Cholangiocarcinoma","Pancreatic Ductal Adenocarcinoma (PDAC)","Esophageal Squamous Cell Carcinoma (ESCC)","Gastric Cancer (GC)",[409,410,411,412,413],"Noninvasive screening","Circulating miRNA","Machine learning","Gastrointestinal cancer","Blood-based cancer detection","2025-11-24",{"date":416,"type":38},"2025-11-26",{"date":418,"type":38},"2024-06-21",{"date":420,"type":22},"2026-06-18",{"name":422,"class":45},"City of Hope Medical Center",{"id":424,"slug":425,"hasResults":12,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":4,"eligibilityCriteria":429,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":430,"enrollmentInfo":431,"targetDuration":4,"studyType":136,"phases":4,"briefSummary":432,"conditions":433,"keywords":434,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":442,"locationsCount":46},"100574277","crc-screening-in-unscreened-individuals-45-54-100574277","NCT06757192","CRC Screening in Unscreened Individuals 45-54","Initiating Colorectal Cancer Screening in Unscreened Individuals 45 to 54","PATIENTS\n\nInclusion Criteria:\n\n* Individuals aged 45-54\n* Individuals who are patients at the health center\n* Individuals that are willing and able to give verbal\u002Fwritten consent\n\nExclusion Criteria:\n\n* Individuals with a personal history of CRC\n* Individuals with a family history of CRC\n* Individuals with a history of inflammatory bowel disease or high-risk cancer syndrome\n\nSTAFF\n\nInclusion Criteria:\n\n* Individuals ages 18+\n* Individuals working at the health center\n* Individuals that are involved in CRC screening processes at CSHC\n* Individuals that are willing and able to give verbal\u002Fwritten consent","54 Years",{"count":110,"type":22},"The goal of this observational study is to understand the barriers and facilitators to completing colorectal cancer screening from the patient and community health center staff perspective. The main question it aims to answer is to identify system-level determinants of colorectal cancer screening in individuals aged 45 to 54. Participants will be asked to partake in one-time interviews either online or in-person and community health center staff will also be asked to take an online survey.",[28],[65],"2025-11-12",{"date":437,"type":38},"2025-11-13",{"date":439,"type":38},"2025-06-16",{"date":441,"type":22},"2029-08-31",{"name":443,"class":45},"Massachusetts General Hospital",{"id":445,"slug":446,"hasResults":12,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":450,"eligibilityCriteria":451,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":452,"targetDuration":4,"studyType":136,"phases":4,"briefSummary":454,"conditions":455,"keywords":456,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":435,"lastUpdatePostDateStruct":457,"startDateStruct":458,"completionDateStruct":459,"leadSponsor":460,"locationsCount":46},"100574757","positive-fit-to-colonoscopy-closing-the-gap-100574757","NCT06763432","Positive Fit to Colonoscopy: Closing the Gap","Fit Abnormal to Colonoscopy: Equity in Screening Completion (FACES)","FACES","Inclusion Criteria:\n\n* Individuals aged 45-75\n* Individuals who are patients at Codman Square Health Center\n* Individuals that are willing and able to give verbal\u002Fwritten consent\n\nExclusion Criteria:\n\n* Individuals with a personal history of colorectal cancer\n* Individuals with a family history of colorectal cancer\n* Individuals with a history of inflammatory bowel disease or high-risk cancer syndrome",{"count":453,"type":22},45,"The goals of this proposal are to: (1) identify patient- and system-level determinants of diagnostic colonoscopy after positive FIT; (2) identify patient- and system-level equity-driven implementation strategies for diagnostic colonoscopy after positive FIT matched to determinants; and (3) pilot test patient- and systems-level implementation strategies to increase rate of colonoscopy after positive FIT and determine feasibility and acceptability of strategies using mixed methods",[28],[65],{"date":437,"type":38},{"date":439,"type":38},{"date":441,"type":22},{"name":443,"class":45},{"id":462,"slug":463,"hasResults":12,"nctId":464,"briefTitle":465,"officialTitle":466,"acronym":467,"eligibilityCriteria":468,"healthyVolunteers":55,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":469,"targetDuration":4,"studyType":23,"phases":471,"briefSummary":473,"conditions":474,"keywords":476,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":479,"lastUpdatePostDateStruct":480,"startDateStruct":482,"completionDateStruct":484,"leadSponsor":485,"locationsCount":46},"100609470","phase-4-cleansing-options-in-out-patient-setting-to-improve-tolerance-coop-sit-trial-100609470","NCT07215000","Cleansing Options in Out-Patient Setting to Improve Tolerance (COOP SIT) Trial","Cleansing Options in Outpatient Setting to Improve Tolerance (COOP SIT) Trial","COOP SIT","Inclusion Criteria:\n\n* Adults over age of 18 years undergoing outpatient colonoscopy for various indications, ability to consent in English or Spanish. Patients will still be allowed to join if there is a history of colorectal cancer or previous surgery\n\nExclusion Criteria:\n\n* Patient is less than 18 years of age, any pregnant or nursing women, unable to consent, or patient is incarcerated.",{"count":470,"type":22},300,[472],"PHASE4","The purpose of this research is to compare patient preferences for two bowel preparation options: low-volume tablets (Suflave\u002FSutab) versus the standard colon preparation using Golytely (polyethylene glycol). The study aims to enroll approximately 300 patients, who will be randomly assigned to one of the two preparation methods in a 2:1 ratio prior to their scheduled colonoscopy appointments. Surveys will be conducted both before and after the procedures.\n\nThis project will be conducted over a 12-month period and seeks to compare patient experience of both preparation methods in an outpatient setting. The study will evaluate the rate of preparation completion, patient satisfaction, tolerance of the solutions, and the endoscopic adequacy of each method.\n\nEligible participants are patients aged 18 or older with upcoming colonoscopy appointments who can provide informed consent in English or Spanish. There is no health risks associated with this study, as both bowel preparation methods are FDA-approved and commonly used in clinical practice.",[28,475],"Bowel Cleansing for Colonoscopy",[477,478],"Colorectal cancer screening","Bowel cleansing for colonoscopy","2025-10-08",{"date":481,"type":38},"2025-10-09",{"date":483,"type":38},"2025-10-01",{"date":388,"type":22},{"name":486,"class":45},"Morehouse School of Medicine",{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":4,"eligibilityCriteria":493,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":494,"targetDuration":4,"studyType":23,"phases":496,"briefSummary":497,"conditions":498,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":500,"lastUpdatePostDateStruct":501,"startDateStruct":503,"completionDateStruct":504,"leadSponsor":506,"locationsCount":391},"100607014","implementation-intention-planning-guide-for-fit-colon-cancer-screening-100607014","NCT07183046","Implementation Intention Planning Guide for FIT Colon Cancer Screening","Impact of an Implementation Intention Planning Guide on Fecal Immunochemical Tests (FIT) Completion Rates","Inclusion Criteria:\n\n* Age 45-75\n* Cared for by primary care at General Internal Medicine Clinic, Dartmouth-Hitchcock Medical Center (Lebanon, NH), Dartmouth Hitchcock Clinics Heater Road Primary Care (Lebanon, NH), Dartmouth Hitchcock Clinics Lyme Primary Care (Lyme, NH), or White River Junction Veterans Affairs Medical Center (White River Junction, VT) OR eligible for FIT through VA Mailed FIT Program\n\nExclusion Criteria:\n\n* none",{"count":495,"type":22},1600,[25],"Fecal immunochemical tests (FIT) are a primary method of screening for colorectal cancer (CRC). Implementation intention planning involves encouraging completion or eliminating barriers for the participant to make a plan to complete a behavior or activity. This randomized control study seeks to answer whether the addition of an implementation intention guide impacts behaviors when completing FIT screening. The primary objective includes determining if the implementation intention guide increases completion rate of screening FIT. The secondary objectives is whether this intervention decreases the lab sample rejection rate and reduces the duration between sample collection and laboratory receipt\u002Fevaluation of screening FIT.",[499,28],"Fecal Immunochemical Test","2025-09-18",{"date":502,"type":38},"2025-09-19",{"date":483,"type":22},{"date":505,"type":22},"2026-06-30",{"name":507,"class":45},"Dartmouth-Hitchcock Medical Center",{"id":509,"slug":510,"hasResults":12,"nctId":511,"briefTitle":512,"officialTitle":513,"acronym":514,"eligibilityCriteria":515,"healthyVolunteers":55,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":516,"targetDuration":4,"studyType":23,"phases":518,"briefSummary":519,"conditions":520,"keywords":527,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":534,"lastUpdatePostDateStruct":535,"startDateStruct":537,"completionDateStruct":539,"leadSponsor":541,"locationsCount":543},"100605106","optical-diagnosis-of-neoplasia-using-artificial-intelligence-100605106","NCT07158203","Optical Diagnosis of Neoplasia Using Artificial Intelligence","Assistance for Optical Diagnosis of Neoplasia Using Artificial Intelligence (FAIR Study)","FAIR","Endoscopists who meet the following inclusion\u002Fexclusion criteria Inclusion criteria\n\n* Endoscopists experienced with more than 100 colonoscopies. Exclusion criteria\n* Endoscopists who are involved in the development of the protocol of the present study.\n\nInclusion and exclusion criteria for the study videos. Inclusion criteria.\n\n* Videos with a duration of 15 seconds including both WL and NBI.\n* Videos with diminutive polyps with confirmed pathology. Exclusion criteria.\n* Videos with no clear image of the polyps.\n* Videos with more than one polyp on-screen.\n* Inflammatory bowel disease\n* Polyposis\n* Hereditary colorectal disease\n* Videos which CADx cannot provide sufficient number of outputs.",{"count":517,"type":22},70,[25],"Computer-aided diagnosis (CADx) for colonoscopy aims to enhance optical diagnosis but often underperforms when used alongside humans due to under-reliance on AI. Psychological interventions like cognitive forcing, such as delaying CADx suggestions, may improve human-AI interaction by fostering critical assessment. However, their impact on patient-important outcomes remains unexplored.\n\nThe investigators will conduct an ex-vivo randomized study with 70 endoscopists assessing 100 polyp videos (≤5 mm) using a CADx tool (GI Genius, Medtronic). Participants will be randomized to either:\n\n* Intervention group: CADx suggestions will be shown in the last 3 seconds of the 15 second polyp video.\n* Control group: CADx suggestions will be shown in real-time throughout the playback of the 15 second polyp video.\n\nThe primary endpoint is sensitivity for high-confidence neoplasia detection, with secondary endpoints assessing endoscopists' reliance on AI.\n\nCADx systems on the market function in various ways, such as real-time, delayed, or on-demand diagnosis. Our study aims to inform users and manufacturers whether cognitive forcing through delayed CADx suggestions enhances human-AI interaction, leading to improved clinical outcomes.",[521,32,522,523,28,524,525,526],"Polyps Colorectal","Optical Biopsy","Colorectal Cancer Control and Prevention","Behavior Change","Psychological Factors","Psychological Intervention",[528,529,530,531,532,533],"behaviour","optical biopsy","colonoscopy","CADx system","colorectal polyps","psychological intervention","2025-08-28",{"date":536,"type":38},"2025-09-05",{"date":538,"type":22},"2025-09",{"date":540,"type":22},"2025-12",{"name":542,"class":45},"Fundacin Biomedica Galicia Sur",2,{"id":545,"slug":546,"hasResults":12,"nctId":547,"briefTitle":548,"officialTitle":549,"acronym":550,"eligibilityCriteria":551,"healthyVolunteers":55,"sex":17,"minAge":84,"maxAge":4,"enrollmentInfo":552,"targetDuration":4,"studyType":136,"phases":4,"briefSummary":554,"conditions":555,"keywords":558,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":562,"startDateStruct":564,"completionDateStruct":566,"leadSponsor":568,"locationsCount":46},"100582517","pilot-study-for-colorectal-cancer-and-advanced-adenoma-detection-with-the-mainz-biomed-colorectal-cancer-test-100582517","NCT06864338","Pilot Study for Colorectal Cancer and Advanced Adenoma Detection With the Mainz Biomed Colorectal Cancer Test","Pilot Study for Colorectal Cancer and Advanced Adenoma Detection With the Mainz Biomed Colorectal Cancer Test (eAArly DETECT)","eAArly DETECT","Group 1: Screening Group Inclusion Criteria\n\n1. Subject is any sex and ≥45 years of age\n2. Subject must be advised to have or be scheduled for a screening colonoscopy\n3. Subject is at average risk for colorectal cancer according to the United States Preventive Services Task Force (USPSTF) guidelines, including:\n\n   * no prior diagnosis of colorectal cancer, adenomatous polyps, or inflammatory bowel disease\n   * no family history of colorectal cancer (defined as one or more first degree relatives including parent, sibling, or child)\n   * no personal diagnosis or family history of known genetic disorders that predispose them to a high lifetime risk of colorectal cancer including:\n\n     * Inflammatory bowel disease (IBD) including chronic ulcerative colitis (CUC) and Crohn's disease\n     * Familial adenomatous polyposis (also referred to as \"FAP\", including attenuated FAP)\n     * Hereditary non-polyposis colorectal cancer syndrome (also referred to as \"HNPCC\" or \"Lynch Syndrome\")\n     * Other hereditary cancer syndromes including but are not limited to Peutz-Jeghers Syndrome, MYH-Associated Polyposis (MAP), Gardner's Syndrome, Turcot's (or Crail's) Syndrome, Cowden's Syndrome, Juvenile Polyposis, Neurofibromatosis and Familial Hyperplastic Polyposis\n     * Cronkhite Canada Syndrome\n4. Subject can understand the study procedures, and is able to provide consent to participate in the study and authorizes release of relevant protected health information through reviewing and consenting to a Health Insurance Portability and Accountability Act (HIPAA) medical release form\n5. Subject is able and willing to provide stool samples within ninety (90) days before the colonoscopy procedure\n6. Subject is able and willing to undergo a colonoscopy after providing a stool sample Exclusion Criteria\n\n1\\. Subject had any precancerous findings on most recent colonoscopy. This does not include non-neoplastic polyps and\u002For hyperplastic polyps of any size (Note: tissue biopsies that result in no histopathology findings are acceptable) 2. Subject has a history of abnormal imaging suggesting colorectal cancer (e.g., colonography, MRI, CT, barium enema) 3. Subject has a history of any of the following cancers: oral, head and neck, lung, esophagus, gastric, biliary\u002Fliver, pancreatic, small bowel, or appendiceal 4. Subject has had a positive non-invasive screening diagnostic within the associated recommended intervals\n\n* High-sensitivity fecal occult blood test or fecal immunochemical test within the previous twelve (12) months\n* sDNA-FIT test within the previous thirty-six (36) months 5. Subject has had a colonoscopy in the previous nine (9) years (not including failed\u002F aborted colonoscopy e.g., due to failed preparation, inability to reach the cecum, patient instability during the procedure, etc.) 6. Subject has had a prior colorectal resection for any reason other than sigmoid diverticular disease 7. Indication for colonoscopy due to overt rectal bleeding (e.g., hematochezia or melena) within the previous thirty (30) days (Note: blood on toilet paper, after wiping, does not constitute rectal bleeding) 8. Subject has any condition that in the opinion of the investigator should preclude participation in the study\n\nGroup 2: Diagnostic Group Inclusion Criteria\n\n1. Subject is any sex and ≥ 18 years of age\n2. Subject is able and willing to give informed consent\n3. Through imaging, a positive non-invasive screening test, or colonoscopy requiring additional intervention subject is suspected or known to have Colorectal Cancer or Advanced Adenoma\n4. Subject has not yet been treated (e.g., ablation, surgical resection, radiation, chemotherapy, etc.) and still has at least one intact or partially intact lesion\n5. Subject must have a diagnostic colonoscopy or surgical intervention scheduled within 90 days of sample collection\n6. Subject can understand the study procedures and is able to provide consent to participate in the study and authorizes release of relevant protected health information through reviewing and consenting to a Health Insurance Portability and Accountability Act (HIPAA) medical release form\n7. Subject is able and willing to provide stool samples within ninety (90) days of enrollment and before any treatment procedures are initiated Exclusion Criteria\n\n1\\. Subject has had a tumor or malignancy other than colorectal cancer identified within the past five years (does not include non-melanoma skin cancer) 2. Subject has been previously diagnosed with inflammatory bowel disease (ulcerative colitis or Crohn's disease) 3. Subject has any condition that in the opinion of the investigator should preclude participation in the study",{"count":553,"type":22},2700,"The Mainz Biomed Colorectal Cancer Screening Test is being studied for its performance in the identification of the presence of colorectal cancer (CRC) or advanced adenoma (AA) in the colon in patients at average risk for colorectal cancer.",[28,556,557],"Colorectal Cancer Metastatic","Colon Adenocarcinoma",[31,559,560],"Colorectal cancer screening test","advanced adenoma screeing test","2025-08-08",{"date":563,"type":38},"2025-08-12",{"date":565,"type":38},"2022-12-18",{"date":567,"type":22},"2025-11-30",{"name":569,"class":124},"Mainz Biomed",{"id":571,"slug":572,"hasResults":12,"nctId":573,"briefTitle":574,"officialTitle":575,"acronym":576,"eligibilityCriteria":577,"healthyVolunteers":55,"sex":17,"minAge":108,"maxAge":4,"enrollmentInfo":578,"targetDuration":4,"studyType":23,"phases":579,"briefSummary":580,"conditions":581,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":582,"lastUpdatePostDateStruct":583,"startDateStruct":585,"completionDateStruct":587,"leadSponsor":589,"locationsCount":4},"100588003","robotic-colonoscopy-using-the-triton-40-system-in-adults-for-screening-surveillance-and-diagnosis-of-lower-gastrointestinal-conditions-100588003","NCT06935734","Robotic Colonoscopy Using the Triton 4.0 System in Adults for Screening, Surveillance, and Diagnosis of Lower Gastrointestinal Conditions","Colonoscopy With a Robotic Endoscope, The CARE I Study","CARE I","Inclusion Criteria\n\n1. Age ≥ 22 years\n2. Adults indicated for elective screening, surveillance or diagnostic colonoscopy\n3. Subject is willing and able to provide written informed consent prior to receiving any non-standard of care Clinical Investigation Plan specific procedures\n4. Subject is willing and able to comply with all Clinical Investigation Plan required preparation and follow- up visits -\n\nExclusion Criteria:\n\nInitial Screening \u002F Pre-Operative:\n\n1. Any medical or physical condition\u002Flimitation that would contraindicate a conventional colonoscopy. This assessment will be made by the investigator.\n2. Any active implantable medical devices (e.g., pacemakers, defibrillators)\n3. Previous failed colonoscopy (except for inadequate bowel preparation)\n4. BMI \\> 45 kg\u002Fm2\n5. Pregnant participants, women of reproductive potential (pre-menopausal and\u002For no history of hysterectomy), confirmed by a positive pregnancy test (serum).\n6. Surgically altered colonic anatomy\n7. History of colorectal cancer, inflammatory bowel disease, polyposis syndrome, hereditary nonpolyposis colorectal cancer (Lynch) syndrome, sclerosing encapsulating peritonitis, active diverticulitis in last 6 months or toxic megacolon\n8. Lower gastrointestinal bleeding within 28 days prior to the colonoscopy day\n9. Known bleeding tendency such as hemophilia or coagulation factor deficiencies\n10. Patient receiving antiplatelet or anticoagulation therapy apart from low-dose aspirin\n11. Known colonic stricture\n12. Known risk factors for abdominal adhesions such as history of complex abdominal or pelvis surgical procedures, based on investigator assessment\n13. Known abdominal wall hernias\n14. History of radiotherapy to the abdomen or pelvis\n15. History of mesenteric ischemia\n16. Known coronary ischemia or cardiovascular stroke within 3 months prior to the colonoscopy procedure\n17. Contraindication to the proposed sedation \u002F anesthesia\n18. Received any investigational medicine or treatment within 28 days prior to the colonoscopy procedure\n19. Received or planning to receive any other endoscopic procedure within 4 weeks prior and 2 weeks after the colonoscopy procedure\n20. Participation in any concurrent clinical trial that may impact the results of this study\n\n    Intra-Operative Exclusion Criteria:\n21. Inadequate Bowel Preparation, Boston Bowel Prep Scale Score (after cleansing) \\\u003C 2 in any section\n22. Failed conventional colonoscopy or polypectomy\u002Fbiopsy performed during the conventional colonoscopy procedure in Phase A\n23. Any presenting condition discovered intraoperatively that in the opinion of the investigator would make participating in this study not in the participant's\u002Fpatient's best interest. For example, presence of a stricture or tight sigmoid that would make passing an overtube risky for the patient\n24. Any condition, in the opinion of the Investigator, that is unstable and could jeopardize the safety of the subject and their compliance in the study",{"count":192,"type":22},[25],"This study is a prospective, single-arm, non-randomized, single site first-in-human study and will be conducted in two phases, where Phase A will serve to evaluate the safety of the Triton 4.0 System to perform screening, surveillance and diagnostic colonoscopies, and Phase B will evaluate the safety and efficacy of the Triton 4.0 System to perform screening, surveillance and diagnostic colonoscopies.",[32,28,114,115],"2025-04-11",{"date":584,"type":38},"2025-04-20",{"date":586,"type":22},"2025-04-14",{"date":588,"type":22},"2025-07-31",{"name":123,"class":124},{"id":591,"slug":592,"hasResults":12,"nctId":593,"briefTitle":594,"officialTitle":595,"acronym":4,"eligibilityCriteria":596,"healthyVolunteers":55,"sex":17,"minAge":84,"maxAge":19,"enrollmentInfo":597,"targetDuration":4,"studyType":23,"phases":599,"briefSummary":600,"conditions":601,"keywords":605,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":613,"lastUpdatePostDateStruct":614,"startDateStruct":616,"completionDateStruct":617,"leadSponsor":619,"locationsCount":46},"100585701","artificial-intelligence-ai-technology-may-help-patients-to-understand-bowel-preparation-better-before-they-go-for-colonoscopythis-study-attempts-to-leverage-ai-chatbot-in-counselling-patients-to-improve-bowel-cleanliness-reduce-anxiety-as-well-as-increase-procedural-satisfaction-100585701","NCT06905782","Artificial Intelligence (AI) Technology May Help Patients to Understand Bowel Preparation Better Before They go for Colonoscopy.This Study Attempts to Leverage AI Chatbot in Counselling Patients to Improve Bowel Cleanliness, Reduce Anxiety as Well as Increase Procedural Satisfaction","Prospective Single Blinded Randomized Control Trial on the Effectiveness of Using Large Language Model Artificial Intelligence Chatbot to Improve Boston Bowel Preparation Score (BBPS) for Colonoscopy Preparation","Inclusion Criteria:\n\n* All scheduled colonoscopy with indication\n* Adequate digital literacy\n* Adequate language literacy with Malay and English language\n\nExclusion Criteria:\n\n* Patients with memory impairment due to previous stroke, dementia or Alzheimer's disease\n* Diagnosed with clinical anxiety",{"count":598,"type":22},96,[25],"Traditional pre-colonoscopy counselling requires significant time from healthcare workers to explain procedures, limiting efficiency and patient turnover. Inadequate bowel preparation exacerbates this issue, leading to repeat procedures and increased costs. However, no study has yet evaluated the effectiveness of AI in improving the Boston Bowel Preparation Scale (BBPS) for colonoscopy preparation. By addressing this gap, AI chatbots could provide personalized guidance, reduce healthcare worker burden, improve preparation quality, and enhance patient experience.This research attempts to evaluate the effectiveness of using Artificial intelligence (AI) chat bot to improve bowel preparation, anxiety level and patient's satisfaction among colonoscopy patients in Hospital Tuanku Muhriz (HCTM), compared to conventional instructions",[28,602,603,604],"Colon Polyps and Adenomas","Bowel Preparation Quality","Artificial Intelligence (AI)",[142,606,530,607,608,609,610,611,612,227],"colon polyp","bowel preparation","Boston Bowel Preparation Score (BBPS)","artificial intelligence","AIChatbot","large language model","patient satisfaction","2025-03-24",{"date":615,"type":38},"2025-04-01",{"date":615,"type":22},{"date":618,"type":22},"2026-02-02",{"name":620,"class":45},"National University of Malaysia",{"id":622,"slug":623,"hasResults":12,"nctId":624,"briefTitle":625,"officialTitle":626,"acronym":627,"eligibilityCriteria":628,"healthyVolunteers":55,"sex":17,"minAge":133,"maxAge":4,"enrollmentInfo":629,"targetDuration":4,"studyType":136,"phases":4,"briefSummary":631,"conditions":632,"keywords":633,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":635,"lastUpdatePostDateStruct":636,"startDateStruct":638,"completionDateStruct":640,"leadSponsor":642,"locationsCount":46},"100563781","prospective-collection-of-samples-to-enable-the-development-of-natera-screening-assay-for-early-cancer-detection-100563781","NCT06620627","Prospective Collection of Samples to Enable the Development of Natera Screening Assay for Early Cancer Detection","Prospective Collection of Samples to Enable the Development of Natera Screening Assay for Early Cancer Detection (PROCEED-CRC)","PROCEED-CRC","Inclusion Criteria:\n\n1. 40 years of age or older at time of consent.\n2. Planning or intending to undergo asymptomatic screening colonoscopy.\n3. Able to tolerate venipuncture for research draw(s).\n4. Able and willing to provide blood samples within the 120 days prior to a colonoscopy procedure.\n5. Willing and able to comply with the study visit schedule and study requirements.\n6. Signed informed consent(s) must be obtained prior to participation in the study\n\nExclusion Criteria:\n\n1. Any prior history of any kind of malignancy (exception: participants who have undergone surgical removal of skin squamous cell or basal cell cancer may be enrolled provided the procedure was completed at least 12 months prior to the date of provision of informed consent for the study)\n2. Had a complete colonoscopy with adequate bowel preparation in the previous nine (9) years.\n3. Undergoing diagnostic colonoscopy for investigation of symptoms such as unexplained and long-lasting diarrhea, overt rectal bleeding, e.g., hematochezia or melena, within the previous 30 days. (Blood on toilet paper, after wiping, does not constitute rectal bleeding)\n4. Undergone colorectal cancer screening within the associated recommended intervals\n\n   1. FOBT\u002FFIT within the previous 12 months\n   2. FIT-DNA test within the previous 36 months\n   3. Blood-based CRC screening test within the previous 36 months\n   4. Computed tomography colonography CTC within the previous 5 years\n   5. Flexible sigmoidoscopy within the previous 5 years\n5. Precancerous findings on most recent colonoscopy. This does not include benign, and\u002For hyperplastic polyps of any size (Note: Tissue biopsies that result in no histopathology findings are acceptable)\n6. Had a prior colorectal resection for any reason other than sigmoid diverticular disease\n7. Diagnosis or personal history of any of the following high-risk conditions for colorectal cancer:\n\n   1. Inflammatory bowel disease (IBD) including chronic ulcerative colitis (CUC) and Crohns disease\n   2. Familial adenomatous polyposis (also referred to as FAP, including attenuated FAP)\n   3. Hereditary non-polyposis colorectal cancer syndrome (also referred to as HNPCC or Lynch Syndrome)\n   4. Other hereditary cancer syndromes including but are not limited to Peutz-Jeghers Syndrome, MYH-Associated Polyposis (MAP), Gardners Syndrome, Turcots (or Crails) Syndrome, Cowdens Syndrome, Juvenile Polyposis, Cronkhite-Canada Syndrome, Neurofibromatosis and Familial Hyperplastic Polyposis",{"count":630,"type":22},5000,"The PROCEED-CRC study will prospectively collect blood samples from participants who are at average risk of colorectal cancer (CRC). Samples will be used for research use and the development of a blood-based CRC screening test.",[28],[142,634],"colon cancer","2025-01-28",{"date":637,"type":38},"2025-01-29",{"date":639,"type":38},"2024-01-26",{"date":641,"type":22},"2025-10-31",{"name":643,"class":124},"Natera, Inc.",{"id":645,"slug":646,"hasResults":12,"nctId":647,"briefTitle":648,"officialTitle":649,"acronym":4,"eligibilityCriteria":650,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":651,"targetDuration":4,"studyType":136,"phases":4,"briefSummary":652,"conditions":653,"keywords":655,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":657,"lastUpdatePostDateStruct":658,"startDateStruct":660,"completionDateStruct":662,"leadSponsor":664,"locationsCount":4},"100575481","dynamics-lynchdna-methylation-analysis-in-stool-for-screening-of-lynch-syndrome-associated-colorectal-cancer-100575481","NCT06772844","DYNAMICS-LYNCH：DNA Methylation Analysis in Stool for Screening of Lynch Syndrome-Associated Colorectal Cancer","DNA Methylation Analysis in Stool Samples for Screening of Lynch Syndrome-Associated Colorectal Cancer","Inclusion Criteria:\n\n* Informed consent: patients are required to participate voluntarily and sign an informed consent form in writing；Patients diagnosed with Lynch syndrome；Agree to collect and send stool specimens for methylation sequencing as required；Willingness to undergo long-term follow-up and three rounds of methylation screening\n\nExclusion Criteria:\n\n* Patients with confirmed familial adenomatous polyposis or other hereditary colorectal cancers that are not Lynch syndrome；Patients who are unable to obtain a fecal specimen or whose specimen is substandard for follow-up testing；Patients diagnosed with colorectal cancer or currently undergoing surgery；Failure to sign informed consent",{"count":350,"type":22},"Colorectal cancer (CRC) has high incidence and mortality rates globally. Over 1 million new cases are diagnosed annually, and about 600,000 people die from the disease each year. In China, CRC ranks third in incidence and fifth in mortality. Its rates are rising due to lifestyle changes and an aging population.\n\nAround 30% of CRC cases have a hereditary component, including familial adenomatous polyposis (FAP) and Lynch syndrome. Lynch syndrome, or hereditary non-polyposis colorectal cancer (HNPCC), accounts for 3%-5% of CRC cases. Early diagnosis, screening, and prophylactic surgery can reduce CRC mortality by 7%-42%, and mortality from endometrial and ovarian cancers by 1%-6%. Intensive screening is essential for Lynch syndrome patients, who are at high risk for CRC.\n\nDue to the lack of early symptoms, many CRC cases are diagnosed in later stages, causing financial strain on patients, families, and society. Screening is an effective tool in reducing CRC-related mortality by more than 50%. In developed countries such as the U.S., U.K., and Japan, CRC screening is integrated into public health programs, emphasizing its role in prevention.\n\nIn China, CRC screening mainly involves the fecal occult blood test followed by colonoscopy, but this method faces challenges. First, the fecal occult blood test lacks sufficient sensitivity, leading to underdiagnosis. Second, colonoscopy is invasive with low patient acceptance. It also requires specialized facilities, advanced equipment, and skilled endoscopists, limiting its accessibility. Given China's large population and limited healthcare resources, universal colonoscopy screening is challenging, resulting in low screening rates.\n\nTo address these challenges, we propose replacing part of colonoscopy screening with DNA methylation testing of fecal samples. Self-sampling methylation screening could ease the strain on healthcare resources and improve patient compliance. By combining methylation screening with colonoscopy, we aim to reduce colonoscopy frequency and enhance overall compliance.\n\nThis study will include three rounds of methylation screening with colonoscopy as the control, involving 400 Lynch syndrome patients. The goal is to develop new screening criteria for this high-risk group, reduce colonoscopy frequency, and ultimately lower CRC incidence in Lynch syndrome patients.",[28,654],"Lynch Syndrome",[656,142,172],"lynch syndrome","2025-01-13",{"date":659,"type":38},"2025-01-15",{"date":661,"type":22},"2025-01-10",{"date":663,"type":22},"2028-12-31",{"name":665,"class":45},"Sun Yat-sen University"]